Five-year survival with upfront bortezomib-based regimens lags behind that with upfront ASCT (55% versus 84%) (18, 19) (23) . Bortezomib is a boronic acid dipeptide that inhibits the 20S proteasome by binding to the catalytic b subunits lining the inner ring of the 20S core particle in a reversible manner (23, 24) .
Ixazomib is a second-generation boronic acid dipeptide proteasome inhibitor that binds reversibly to the 20S proteasome. Because of a shorter proteasome dissociation half-life, ixazomib has significantly larger volume of distribution and greater tumor proteasome inhibition than bortezomib in vivo, allowing for higher doses of administration and greater plasma exposure (24) . Compared to lenalidomide and dexamethasone alone, addition of ixazomib reduced disease progression or death in patients with relapsed/ refractory MM with a hazard ratio (HR) of 0.74 (25) .
No excess of adverse events was seen with ixazomib.
A phase I/II trial of ixazomib in 27 patients with relapsed/refractory AL showed encouraging hematologic (52%) and organ (56%) response rates with only 3 patients experiencing dose-limiting toxicity (NCT01318902) (26) . A phase III trial of ixazomib in the AL population is ongoing (NCT01659658) ( Table 1) .
Carfilzomib is a modified epoxyketone that binds the 20S proteasome irreversibly and with higher selectivity than bortezomib. As compared with lenalidomide and dexamethasone alone, the addition of carfilzomib in relapsed MM improved 24-month survival by 21% and also led to significant improvement in hematologic response rate (27) . Cardiovascular toxicities (hypertension, cardiac failure, and ischemic heart disease) were among the major adverse effects.
In a phase I/II trial of carfilzomib monotherapy in 28 patients with previously treated AL, 63% showed Isatuximab is a chimeric IgG1 monoclonal antibody that targets CD38 as an allosteric antagonist (41).
In vivo, isatuximab showed antitumor activity in multiple cancer models including MM, lymphoma, and leukemia. In a phase Ib trial of isatuximab, lenalidomide, and dexamethasone for relapsed/refractory multiple myeloma, the overall hematologic response rate was 56% and median PFS was Zhang et al.
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FUTURE DIRECTIONS
With the emergence of multiple novel therapeutics for AL and ATTR, there is an urgent need to define optimal drug combinations and sequences of drug delivery to reduce morbidity and mortality amongst patients with AL-CA and ATTR-CA. This is particularly important in the treatment of AL-CA, although large randomized clinical trials in this population are challenging due to low disease prevalence and poor
